🔬 Their partnership combines Nuclera’s eProtein Discovery System with Cytiva’s Biacore SPR technology.
🚀 This innovation can reduce protein characterization time from months to just five days.
💡 Clinically significant proteins like BTK and VEGF will aid in drug R&D efforts.
Introduction:
The collaboration between Nuclera and Cytiva represents a significant advancement in the field of protein characterization for pharmaceutical research and development (R&D). By integrating innovative technologies, the partnership aims to expedite the production, purification, and characterization of proteins, which are crucial for drug development processes.
- Nuclera and Cytiva’s collaboration focuses on enhancing the speed and efficiency of protein characterization necessary for pharma research and development.
- The collaboration utilizes Nuclera’s eProtein™ Discovery System alongside Cytiva’s Biacore™ surface plasmon resonance (SPR) technology.
- Proteins are essential as they constitute 95% of drug targets, underscoring the importance of rapid access and analysis in drug development.
- The partnership has significantly reduced the time to produce and characterize proteins from months to just five days.
- Demonstrations have shown the successful production of proteins like Bruton’s Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF), highlighting the capabilities of the integrated systems.
Conclusion:
The collaboration between Nuclera and Cytiva not only streamlines protein production and characterization but also sets a new standard in the pharmaceutical development landscape. This partnership promises to facilitate quicker drug development processes, ultimately advancing therapeutic solutions for various diseases.
